Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02111772 · ClinicalTrials.gov registry record · NA

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

A NA study, sponsored by University of Virginia.

Completed
Registry status
NA
Development phase
26
Enrollment target

NCT02111772 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02111772, a NA study, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target

Study Summary

In patients with asthma, reactions to allergens in the environment (such as mold, pollen, weed, domestic pets, and dust allergens) play an important role in causing asthma symptoms. However, upper respiratory tract infections, typically those caused by the common cold virus, rhinovirus, can also cause asthma to get worse. In previous studies at the University of Virginia, it was found that mild asthmatics, who had high levels of the allergy antibody (called IgE) in their blood, developed more persistent cold and chest symptoms when they were given an infection with rhinovirus (the most frequent cause of the common cold). The cold symptoms produced by rhinovirus tend to peak during the first 4 -7 days of the cold. These symptoms, including nasal congestion, are similar to what you have experienced with previous colds. This study is being done to learn how a common cold caused by a viral infection affects people with asthma. The goal is to learn how to improve the care of asthma symptoms caused by the common cold virus (called rhinovirus). Most adults experience one or two colds caused by rhinovirus every year. In addition, 75-80% of asthma exacerbations caused by viral infections are caused by this virus, primarily in children. Adults are less likely to experience significant changes in their asthma symptoms when they get colds, because they have developed protective immune responses from previous colds which help diminish symptoms.

Interventions

  • BIOLOGICAL Rhinovirus

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2013-09-01
Est. Completion 2017-04-27
Phase NA

Sponsor

University of Virginia

449 total trials

What the Registry Record Tells You About NCT02111772

The ClinicalTrials.gov registry entry for NCT02111772 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Rhinovirus is the first listed.

NCT02111772 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02111772 about?

NCT02111772 is a clinical study titled "Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic". In patients with asthma, reactions to allergens in the environment (such as mold, pollen, weed, domestic pets, and dust allergens) play an important role in causing asthma symptoms. However, upper respiratory tract infections, typically those caused by the common cold virus, rhinovirus, can also cau...

What is the current status of trial NCT02111772?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2013-09-01. Estimated completion is 2017-04-27.

What interventions are being tested in trial NCT02111772?

The interventions under investigation include: Rhinovirus (BIOLOGICAL).

Who is sponsoring clinical trial NCT02111772?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.